Cargando…

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy

BACKGROUND AND PURPOSE: The objective of this study was to determine the incidence and long-term outcomes of oxaliplatin-induced peripheral neuropathy (OIPN), as well as predictors of its severe form. METHODS: Sixty-nine patients who were taking oxaliplatin for colon cancer were prospectively follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Su-Hyun, Kim, Woojun, Kim, Ji-Hee, Woo, Min Ki, Baek, Ji Yeon, Kim, Sun Young, Chung, Seung Hyun, Kim, Ho Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765261/
https://www.ncbi.nlm.nih.gov/pubmed/29629544
http://dx.doi.org/10.3988/jcn.2018.14.1.81
_version_ 1783292199438385152
author Kim, Su-Hyun
Kim, Woojun
Kim, Ji-Hee
Woo, Min Ki
Baek, Ji Yeon
Kim, Sun Young
Chung, Seung Hyun
Kim, Ho Jin
author_facet Kim, Su-Hyun
Kim, Woojun
Kim, Ji-Hee
Woo, Min Ki
Baek, Ji Yeon
Kim, Sun Young
Chung, Seung Hyun
Kim, Ho Jin
author_sort Kim, Su-Hyun
collection PubMed
description BACKGROUND AND PURPOSE: The objective of this study was to determine the incidence and long-term outcomes of oxaliplatin-induced peripheral neuropathy (OIPN), as well as predictors of its severe form. METHODS: Sixty-nine patients who were taking oxaliplatin for colon cancer were prospectively followed prior to starting chemotherapy and after 4, 8, and 12 cycles of chemotherapy. Thirty-six patients completed the follow-up at 1 year after the end of chemotherapy. The patients were assessed using clinical assessment scales and nerve conduction studies (NCS) at each follow-up visit. RESULTS: By applying the National Cancer Institute Common Toxicity criteria, OIPN was classified as grade 1 in 30 (44%) patients, grade 2 in 25 (36%), and grade 3 in 10 (14%) at the completion of therapy. At 1 year after the treatment, OIPN of grades 1, 2, and 3 was found in 50, 3, and 11% of the patients, respectively. Multivariate analysis showed that reductions of the amplitude of the sensory action potential of >11.5% in the median nerve between baseline and four cycles of chemotherapy (odds ratio=5.603, p=0.031) and of >22.5% in the sural nerve between four and eight cycles of chemotherapy (odds ratio=5.603, p=0.031) were independently associated with the risk of developing grade-3 OIPN. CONCLUSIONS: While the severity of OIPN can improve after oxaliplatin discontinuation, more than half of the patients in this study still had OIPN at 1 year after discontinuation. Early changes in the NCS results for sensory nerves can predict the development of severe OIPN during treatment.
format Online
Article
Text
id pubmed-5765261
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-57652612018-01-12 A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy Kim, Su-Hyun Kim, Woojun Kim, Ji-Hee Woo, Min Ki Baek, Ji Yeon Kim, Sun Young Chung, Seung Hyun Kim, Ho Jin J Clin Neurol Original Article BACKGROUND AND PURPOSE: The objective of this study was to determine the incidence and long-term outcomes of oxaliplatin-induced peripheral neuropathy (OIPN), as well as predictors of its severe form. METHODS: Sixty-nine patients who were taking oxaliplatin for colon cancer were prospectively followed prior to starting chemotherapy and after 4, 8, and 12 cycles of chemotherapy. Thirty-six patients completed the follow-up at 1 year after the end of chemotherapy. The patients were assessed using clinical assessment scales and nerve conduction studies (NCS) at each follow-up visit. RESULTS: By applying the National Cancer Institute Common Toxicity criteria, OIPN was classified as grade 1 in 30 (44%) patients, grade 2 in 25 (36%), and grade 3 in 10 (14%) at the completion of therapy. At 1 year after the treatment, OIPN of grades 1, 2, and 3 was found in 50, 3, and 11% of the patients, respectively. Multivariate analysis showed that reductions of the amplitude of the sensory action potential of >11.5% in the median nerve between baseline and four cycles of chemotherapy (odds ratio=5.603, p=0.031) and of >22.5% in the sural nerve between four and eight cycles of chemotherapy (odds ratio=5.603, p=0.031) were independently associated with the risk of developing grade-3 OIPN. CONCLUSIONS: While the severity of OIPN can improve after oxaliplatin discontinuation, more than half of the patients in this study still had OIPN at 1 year after discontinuation. Early changes in the NCS results for sensory nerves can predict the development of severe OIPN during treatment. Korean Neurological Association 2018-01 2017-12-27 /pmc/articles/PMC5765261/ /pubmed/29629544 http://dx.doi.org/10.3988/jcn.2018.14.1.81 Text en Copyright © 2018 Korean Neurological Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Su-Hyun
Kim, Woojun
Kim, Ji-Hee
Woo, Min Ki
Baek, Ji Yeon
Kim, Sun Young
Chung, Seung Hyun
Kim, Ho Jin
A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title_full A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title_fullStr A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title_full_unstemmed A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title_short A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
title_sort prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765261/
https://www.ncbi.nlm.nih.gov/pubmed/29629544
http://dx.doi.org/10.3988/jcn.2018.14.1.81
work_keys_str_mv AT kimsuhyun aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimwoojun aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimjihee aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT woominki aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT baekjiyeon aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimsunyoung aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT chungseunghyun aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimhojin aprospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimsuhyun prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimwoojun prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimjihee prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT woominki prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT baekjiyeon prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimsunyoung prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT chungseunghyun prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy
AT kimhojin prospectivestudyofchronicoxaliplatininducedneuropathyinpatientswithcoloncancerlongtermoutcomesandpredictorsofsevereoxaliplatininducedneuropathy